Capsida
2 known investors
Capsida Biotherapeutics develops engineered gene therapies for rare and common neurological and ocular diseases using an AAV capsid platform that enables improved brain and retinal delivery compared to naturally occurring capsids. The company targets both central nervous system and ophthalmology conditions across all ages.
Founders & leadership
VG
Viviana Gradinaru
NG
Nick Goeden, Ph.D.Co-founder
NF
Nicholas FlytzanisCo-founder
Investors · 2
In the news
- Press Releases - Capsida Biotherapeuticscapsida.com · 2023
- Capsida Has a New Facility To Manufacture Treatments for ALS and Friedreich’s Ataxiadot.la · 2021
- Capsida Biotherapeutics Raises $140M in Series A Funding - FinSMEsfinsmes.com · 2021
- Capsida Debuts with $140 Million to Advance Next Generation Gene Therapies - Global Genesglobalgenes.org · 2021
- Capsida raises $140 million for targeted AAV gene therapiescen.acs.org · 2021